The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1 by Perez Carrion, Maria et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2018-02-28 
The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon 
MPP+ Treatment by Altering LRRK2 Binding to DRP1 
Maria Perez Carrion 
University of Trento 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Molecular and Cellular Neuroscience Commons, and the Nervous System Diseases 
Commons 
Repository Citation 
Perez Carrion M, Landers JE, Goldwurm S, Piccoli G. (2018). The LRRK2 Variant E193K Prevents 
Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1. Open Access Articles. 
https://doi.org/10.3389/fnmol.2018.00064. Retrieved from https://escholarship.umassmed.edu/oapubs/
3353 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
ORIGINAL RESEARCH
published: 28 February 2018
doi: 10.3389/fnmol.2018.00064
The LRRK2 Variant E193K Prevents
Mitochondrial Fission Upon MPP+
Treatment by Altering LRRK2
Binding to DRP1
Maria Perez Carrion1, Francesca Pischedda1, Alice Biosa2, Isabella Russo2,
Letizia Straniero3, Laura Civiero2, Marianna Guida 4, Christian J. Gloeckner5,6,
Nicola Ticozzi7,8, Cinzia Tiloca7,8, Claudio Mariani9, Gianni Pezzoli9, Stefano Duga3,10,
Irene Pichler4, Lifeng Pan11, John E. Landers12, Elisa Greggio2, Michael W. Hess13,
Stefano Goldwurm8,14*† and Giovanni Piccoli1*†
1Dulbecco Telethon Institute, CIBIO, Università degli Studi di Trento, Trento, Italy, 2Dipartimento di Biologia, Università di
Padova, Padova, Italy, 3Humanitas Clinical and Research Center, Milan, Italy, 4Institute for Biomedicine, Eurac Research,
Affiliated Institute of the University of Lübeck, Bolzano, Italy, 5German Center for Neurodegenerative Diseases (DZNE),
Tübingen, Germany, 6Institute for Ophthalmic Research, Center for Ophthalmology, University of Tübingen, Tübingen,
Germany, 7Dino Ferrari Center, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy,
8Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano, Milan, Italy, 9Parkinson Institute,
ASST Gaetano Pini-CTO, Milan, Italy, 10Department of Biomedical Sciences, Humanitas University, Milan, Italy, 11Shanghai
Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China, 12Department of Neurology, University of
Massachusetts Medical School, University of Massachusetts, Worcester, MA, United States, 13Division of Histology and
Embryology, Innsbruck Medical University, Innsbruck, Austria, 14Department of Neuroscience Rita Levi Montalcini, University
of Turin, Turin, Italy
Edited by:
Shin-ichi Hisanaga,
Tokyo Metropolitan University, Japan
Reviewed by:
Ralf J. Braun,
University of Bayreuth, Germany
Luca Murru,
Consiglio Nazionale delle Ricerche
(CNR), Italy
Etsuro Ohta,
Kitasato University, Japan
*Correspondence:
Stefano Goldwurm
stefano.goldwurm@gmail.com
Giovanni Piccoli
giovanni.piccoli@unitn.it
†These authors share senior
authorship.
Received: 03 November 2017
Accepted: 15 February 2018
Published: 28 February 2018
Citation:
Perez Carrion M, Pischedda F,
Biosa A, Russo I, Straniero L,
Civiero L, Guida M, Gloeckner CJ,
Ticozzi N, Tiloca C, Mariani C,
Pezzoli G, Duga S, Pichler I, Pan L,
Landers JE, Greggio E, Hess MW,
Goldwurm S and Piccoli G (2018)
The LRRK2 Variant E193K Prevents
Mitochondrial Fission Upon MPP+
Treatment by Altering LRRK2 Binding
to DRP1.
Front. Mol. Neurosci. 11:64.
doi: 10.3389/fnmol.2018.00064
Mutations in leucine-rich repeat kinase 2 gene (LRRK2) are associated with familial and
sporadic Parkinson’s disease (PD). LRRK2 is a complex protein that consists of multiple
domains, including 13 putative armadillo-type repeats at the N-terminus. In this study, we
analyzed the functional and molecular consequences of a novel variant, E193K, identified
in an Italian family. E193K substitution does not influence LRRK2 kinase activity. Instead
it affects LRRK2 biochemical properties, such as phosphorylation at Ser935 and affinity
for 14-3-3ε. Primary fibroblasts obtained from an E193K carrier demonstrated increased
cellular toxicity and abnormal mitochondrial fission upon 1-methyl-4-phenylpyridinium
treatment. We found that E193K alters LRRK2 binding to DRP1, a crucial mediator
of mitochondrial fission. Our data support a role for LRRK2 as a scaffolding protein
influencing mitochondrial fission.
Keywords: LRRK2, DRP1, mitochondria, protein interaction, Parkinson’s disease
INTRODUCTION
Parkinson’s disease (PD) is an age-related disorder that affects 2% of the population above 65-years.
PD is related to the progressive loss of dopaminergic neurons in the substantia nigra (Moore et al.,
2005; Poewe et al., 2017) and is clinically characterized by bradykinesia, rigidity and resting
tremor. Although the majority of cases do not correlate with clear genetic causes, mutations in
the Leucine-rich repeat kinase 2 (LRRK2) gene (PARK8; OMIM 609007) have been unequivocally
related to late-onset PD. LRRK2 mutations have been identified in up to 13% of familial PD cases
(Paisán-Ruíz et al., 2004; Zimprich et al., 2004) and also account for 1%–2% of not familial cases
(Aasly et al., 2005; Goldwurm et al., 2005). LRRK2 protein includes some functional domains such
as, from N- to C-terminus armadillo, ankyrin, the namesake leucine-rich repeats, a ROC GTPase
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domain (Ras of complex proteins), a COR dimerization domain
(C-terminal of ROC), a kinase domain and WD40 repeats
(Bosgraaf and Van Haastert, 2003; Mills et al., 2012). Genetic
and functional analyses have correlated several single nucleotide
variants falling in different LRRK2 domains to PD (Paisán-
Ruiz et al., 2013) but only five missense mutations within
the ROC, COR and kinase domains segregate with PD,
being the kinase hyper-activating G2019S mutation the most
common. Emerging data suggest the relevance of domains
outside the LRRK2 enzymatic core. In fact, the characterization
of the G2385R substitution in the WD40 domain as a
pathological variant (Tan, 2006; Tan et al., 2009) that affects
LRRK2 biochemical properties (Rudenko et al., 2012) and
binding to synaptic vesicles (Piccoli et al., 2014; Carrion et al.,
2017) indicates the relevance of LRRK2 domains devoid of
enzymatic activities. Here we investigated the functional impact
of a novel missense variant identified in an Italian family with
three siblings affected by PD, E193K. E193K falls within the
N-terminus, where a cluster of LRRK2-specific repeats organized
as variants of the armadillo repeat structure have been identified
(Marín, 2006; Mills et al., 2012). We found that the E193K
variant affects LRRK2 supra-molecular organization, binding to
DRP1 and cellular and mitochondrial response to 1-methyl-4-
phenylpyridinium (MPP+).
MATERIALS AND METHODS
Subjects
We studied one non-consanguineous family originating from
Southern-Italy with three siblings affected by PD out of
10, and no history of neurological diseases in the previous
generations. Additional DNA samples were obtained from
the Parkinson Institute Biobank: 429 familial PD (at least
on first or second degree relative affected), 179 early-onset
PD (onset <40 years of age), 167 PD cases from the same
geographical area of the index family (Calabria); 960 healthy
controls (age at withdrawal 65 years ± 7). The clinical diagnosis
of PD was established according to the UK Brain Bank
criteria (Hughes et al., 1992, 2001). Patients derived fibroblasts
were obtained from the Parkinson Institute Biobank (part of
the Telethon Genetic Biobank Network http://biobanknetwork.
telethon.it/). This study was approved by the Ethical Committee
‘‘Comitato Etico Milano Area C’’ (http://comitatoeticoareac.
ospedaleniguarda.it/) on the 26/06/2015 (Numero Registro
dei pareri: 370-062015) and was conducted according to the
Declaration of Helsinki and to the Italian legislation on sensitive
personal data recording. Written informed consent was obtained
from all subjects.
Exome Sequencing
Genomic DNA was isolated from peripheral blood with standard
protocols. Exome sequencing was performed in two affected
individuals (G-0502 and G-1350) using an exome array (SeqCap
EZ Human Exome Library v2.0, Nimblegen) adapted for
sequencing on the Illumina HiSeq2000 platform. Alignment
of short reads sequences to the human genome (hg19) was
obtained with BWA (Li and Durbin, 2009) and variant detection
was performed with the GATK software package (McKenna
et al., 2010) according to best practice recommendations. Quality
control and filtering of candidate variants were performed using
an in-house pipeline (Wu et al., 2012). All novel variants
identified through exome sequencing and segregating with PD
in the family were subsequently screened first on a panel of
aged-matched Italian healthy controls (n = 960) and then in an
Italian cohort of healthy subjects (n = 1769) recruited within
the ‘‘Atherosclerosis, Thrombosis, and Vascular Biology Italian
Study Group’’ (ATVB), as previously described (Atherosclerosis,
Thrombosis, and Vascular Biology Italian Study Group, 2003).
Mutation Analysis
The screening for the E193K variant was performed amplifying
a 212bp region surrounding the mutation (primers available
on request), and the obtained PCR products were analyzed by
high-resolution melting (HRM) analysis using a LightCycler 480
(Roche, Basel, Switzerland). Samples that presented an abnormal
melting curve, compatible with a heteroduplex formation, were
subsequently sequenced on an ABI 3130XL sequencer (Thermo
Scientific, Waltham, MA, USA).
Cell Cultures
Human fibroblasts were collected from one PD patient with
E193K LRRK2 mutation who allowed skin biopsy (G-1350)
and two age- and sex-matched healthy controls and G2019S
carriers. Primary fibroblasts were banked at Cell Line and
DNA Biobank from patients affected by Genetic Diseases and
provided at passages 1–2. Cells were grown in Dulbecco’s
Modified Eagle Medium (DMEM; Invitrogen, Carlsbad, CA,
USA) supplemented with 20% FBS (Invitrogen, Carlsbad, CA,
USA), 1% L-glutamine and 1% penicillin/streptomycin (Gibco,
Thermo Fisher). Primary cells were used for all experiments
with less than 10 passages in vitro. N2A (ATCC CCL-131),
HEK293 (ATCC CRL-1573) and HeLa cells (ATCC CL-2) were
grown in DMEM with 10% FBS, 1% L-glutamine and 1%
penicillin/streptomycin. Cells were maintained at a density of
1 × 106 in a 75 cm2 tissue culture flask (Corning, New York,
NY, USA) and incubated at 37◦C under saturating humidity in
5% CO2.
Plasmids and Transfection
Human LRRK2 armadillo domain (aa 1-397) was subcloned
into pDEST15 (N-terminal GST tag) using the Gateway system
(Life Technologies) as described previously (Piccoli et al., 2014).
Full-lengthmyc-hLRRK2, GFP-hLRRK2, RFP-hLRRK2 or Strep-
FLAG-hLRRK2 hLRRK2 and Strep-FLAG 14-3-3ε constructs
were already described (Gloeckner et al., 2006, 2007). The
E193K variant was generated in both vectors by site-directed
mutagenesis using the QuikChange mutagenesis kit (Stratagene).
Strep-FLAG LRRK2 K1906M and Strep-FLAG LRRK2 913-2527
(hereinafter termed as ∆N-terminal) were amplified by PCR
from the LRRK2 cDNA and cloned into pDEST Strep-FLAG
(N-SF-TAP) plasmid as already described (Gloeckner et al.,
2006). Strep-FLAG LRRK2 1-2141 (from now on termed as
∆WD40) was already described (Piccoli et al., 2014). GFP-DRP1
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plasmid was kindly provided by Dr. Van der Bliek (Smirnova
et al., 2001). N2a, HEK293, and HeLa cells were transfected
by lipofection using Lipofectamine 2000 (Life Technologies)
following manufacturer’s instructions and processed 2 days after.
Human fibroblast transfection was performed with AmaxaTM
Basic NucleofectorTM Kit (Lonza). Briefly, for each transfection,
1 × 106 cells were resuspended in 100 µL of nucleofector
solution for mammalian fibroblast and added 3 µg of GFP
or GFP-tagged DRP1 plasmid. The mix was transferred to the
cuvette and nucleofection was performed using A33 programme
on the Amaxa apparatus. Then 500 µL of warm medium were
added to the cells that were plated on 12-mm coverslips for 24 h
before further treatment.
Pull-down, Immuno-precipitation, Filter
Retardation Assay, Western-Blotting and
Antibodies
LRRK2 GST-fusion domains and GST were expressed in the
E. coli BL21 strain (Life Technologies) and purified as described
earlier [13]. Briefly, 5 µg of each GST fusion protein was loaded
onto glutathione-sepharose resin (GE-Healthcare, Freiburg) and
co-incubated with adult mouse brain lysate (1 mg of total
protein). Beads were washed twice with high salt buffer (300 mM
NaCl, 50 mM Tris-HCl, pH 7.4) and samples were eluted in
Laemmli Buffer 2× for 10 min at 55◦C.
For LRRK2 pull-down from heterologous cell lines, 2 days
after transfection cells were solubilized in lysis buffer (150 mM
NaCl, 2 mM EDTA, 50 mM Tris-HCl, 1% NP-40 and
0.25% sodium deoxycholate, pH 7.4) completed with protease
and phosphatase inhibitors (Calbiochem) for 1 h at 4◦C.
LRRK2 was precipitated using Strep-Tactin Superflow resin
(Iba) for 2 h at 4◦C. Washing conditions were performed
with high salt buffer (300 mM NaCl, 50 mM Tris-HCl pH
7.4) and interacting proteins were eluted in Laemmli buffer
2× at 55◦C for 10 min. Pull-down efficiency was judged as
the amount of preys normalized to bait quantity as monitored
by Ponceau staining. In immuno-precipitation assays, 4 µg of
rat anti-LRRK2 (LANK/24D8 clone) antibody or rat anti-IgG
(Abcam) was incubated with 1 mg of protein lysate and loaded
onto protein G-sepharose resin (GE-Healthcare, Freiburg). In
both procedures, resins were extensively washed in Tris-EDTA
buffer (10 mM Tris-HCl, pH8.0, 1 mM EDTA, 150 mM NaCl,
0.2% Triton-X100) and samples eluted with Laemmli buffer
2×. In the filter retardation assay, proteins were extracted on
PBS 1× plus protease and phosphatase inhibitors (Calbiochem)
and bath-sonicated for 6 s. Protein amount was quantified by
Bradford’s method and samples were prepared diluting 10 µg
of total protein in 120 µl of PBS 1× and filtered through
a cellulose acetate membrane and through a nitrocellulose
membrane (both fromGEHealthcare) by using a 96-well vacuum
dot blot system. For protein identification by Western blotting,
samples were loaded onto 4%–12% NuPAGE gels (Invitrogen);
the proteins were transferred onto nitrocellulose membrane (GE
Healthcare) at 82V for 120 min at 4◦C. In all procedures, the
primary antibodies were applied overnight in blocking buffer
(20 mM Tris, pH 7.4, 150 mM NaCl, 0.1% Tween 20, and 5%
non-fat dry milk). Primary antibodies (source in parenthesis)
included: rabbit anti-LRRK2 1:500 (MJFF2, c41-2), rabbit
anti-pSer935 LRRK2 (UDD2-10-12, University of Dundee),
mouse anti-DRP1 1:1000 (clone 8, BD Transduction Systems
Abcam), rabbit anti-pSer616 DRP1 1:1000 (Cell Signalling),
anti-mitofusin 2 (N-terminal) 1:1000 (Sigma), mouse anti-α-
Tubulin 1:3000 (Sigma), mouse anti-β-Actin 1:4000 (Sigma),
mouse anti-Flag 1:1000 (Sigma). Membranes were washed three
times for 10 min with TBS-Tween buffer. The secondary
antibodies HRP-conjugated anti-rabbit or anti-mouse (Jackson
Immunoresearch) were used at 1:7000 dilution. Proteins were
detected using the ECL prime detection system (GE Healthcare).
Images were acquired with the ChemiDoc Touch imaging
system (BioRad), and protein quantification was performed
measuring the optical density of the specific bands with ImageJ
software (NIH).
MTT Reduction Assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay developed byMosmann (Mosmann, 1983)
was performed to measure the cytotoxic effect of MPP+. Human
fibroblasts were seeded in a 96-well plate at a concentration of
5 × 103 cell/cm2 and incubated at 37◦C for 24 h. Then, cells
were treated with MPP+ at different concentrations (1 mM or
3 mM; Sigma) or fresh medium for 24 h (control condition).
To perform the assay, MTT was solubilized at a concentration
of 5 mg/ml in PBS 1× and added to a final concentration of
0.25 mg/ml in medium. Cells were incubated for 2 h at 37◦C.
Then, the medium was decanted, and formazan precipitates were
solubilized in 200µL of DMSO. The absorbance was measured at
570 nm using a spectrophotometer. Cell viability was expressed
setting the control condition as 100% of vitality.
Mitochondrial Morphology, ROS
Production Measurement and
LRRK2 Cellular Distribution
To analyze mitochondrial morphology, human fibroblasts
and Hela cells were seeded on 12-mm glass coverslips and
incubated at 37◦C for 24 h. After transfection, when indicated,
cells were treated with MPP+ (1 mM) or fresh medium
for 24 h and then incubated with 500 nM MitoTracker
Red CMXRos (Molecular Probes, Invitrogen) for 30 min
at 37◦C. Mitochondrial superoxide content in fibroblasts
was characterized by incubation with 2.5 µM Mitosox Red
(Molecular Probes, Invitrogen) for 45 min at 37◦C. To study
LRRK2 cellular localization, RFP-tagged LRRK2 wild-type (WT)
or E193K and GFP vectors were overexpressed in N2A cells for
48 h. In all cases, after incubation period cells were washed with
warm PBS 1× and fixed with 4% paraformaldehyde for 10 min at
room temperature. For nuclear staining, DAPI was prepared at
1:3000 proportion in PBS 1× and incubated for 15 min at room
temperature.
Coverslips were mounted with prolonged reagent
(Life Technologies). Images were acquired with Zeiss
Observer Z1 microscope equipped with Apotome module
using an EC Plan-Neofluar 40×/0.75 Oil objective, pixel
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size 0.114 µm × 0.114 µm or a Plan-Apochromat
100×/1.40 objective, pixel size 0.045 µm × 0.045 µm. The
obtained images provide an axial resolution comparable to
confocal microscopy (Schaefer et al., 2004; Garini et al., 2005).
Cells were randomly chosen in at least four independent
experiments for each condition. All the measurements were
performed with ImageJ software (NIH) using mitochondrial
morphology plugin (developed by Ruben K. Dagda at the
University of Pittsburgh). Parameters were automatically
determined and expressed as mitochondrial content
(percentage of cytosol occupied by mitochondria) and index
of interconnectivity (area/perimeter ratio of mitochondria).
Reactive oxygen species (ROS) content was quantified with
ImageJ software analyzing the integrated density of the
fluorescent signal.
Electron Microscopy
Fibroblasts were plated at days 10–12 after thawing onto
sapphire coverslips and cultured for 2–3 days until ∼70%–80%
confluence. The samples were cryo-fixed using high-pressure
freezing, followed by freeze-substitution and epoxy resin
embedding for thin-section transmission electron microscopy as
previously described (Studer et al., 1989; Hess et al., 2000).
Characterization of Mitochondrial Activity
with High-Resolution Respirometry
The activity of the mitochondrial respiration in fibroblasts was
measured using a high-resolution respirometer (Oxygraph-2k;
Oroboros Instruments, Innsbruck, Austria) as previously
described (Pesta and Gnaiger, 2012). Briefly, oxygen
consumption was measured in cells permeabilized with
digitonin (8 µg/ml) in MiRo5 medium (10 mM KH2PO4,
60 mM lactobionic acid, 20 mM HEPES, 3 mM MgCl2,
0.5 mM EGTA, 20 mM taurine, 110 mM D-Sucrose and
1 mg/ml BSA fatty acid free). For the characterization of
mitochondrial respiration the following characteristics were
assessed: (1) physiological respiratory activity in intact cells
(routine respiration); (2) complex I-, (3) complex II–dependent
respiration, and (4) maximal capacity of the respiratory chain
(MAX: not physiological maximal uncoupled respiration that
is not limited by the enzyme activity of the ATP synthase)
after induction by stepwise titration of carbonyl cyanide
p-(trifluoromethoxy) phenylhydrazone, FCCP (0.5 µM).
Residual oxygen consumption, ROX (respiration attributable
to other cellular oxygen-consuming processes besides the
respiratory chain) was measured after addition of 2.5 µM
antimycin A. ROX was subtracted from the other parameters.
Absolute respiration values were normalized for the total number
of cells (800 × 103/chamber). All reagents were purchased from
Sigma Aldrich.
Kinase and PhosTag Assays
In vitro kinase assay was perfomed as described (Civiero
et al., 2015). Briefly, HEK-293T cells transfected with Strep-Flag
LRRK2 WT, E193K or K1906M and with 3xFlag-Rab8, were
lysed in buffer A [20 mM Tris-HCl pH 7.5, 150 mM NaCl,
1 mM EDTA, Na4O7P2 2.5 mM, -glycerophosphate 1 mM,
NaVO4 1 mM, 0.5% Tween 20, Protease inhibitor cocktail,
1× Complete Mini Protease Inhibitor Cocktail (Roche Applied
Science)]. Cleared lysates (1 ml) were incubated with anti-
FLAG-M2-agarose beads (Sigma) by rotating overnight at 4◦C.
Resin complexes were washed with different buffers (twice with
20 mM Tris–HCl, 500 mM NaCl, 0.5% Tween 20; twice with
20 mM Tris–HCl, 300 mM NaCl, 0.5% Tween 20; twice
with 20 mMTris–HCl, 150 mMNaCl, 0.5% Tween 20; twice with
20 mM Tris–HCl, 150 mM NaCl, 0.1% Tween; and twice with
20 mM Tris–HCl, 150 mM NaCl, 0.02% Tween 20) and proteins
were eluted in kinase buffer (25 mM Tris-HCl pH 7.5, 5 mM
β-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4,
10 mM MgCl2, Tween 0.02% and 150 ng/µl of 3X-FLAG
peptide) for 45 min at 4◦C with shaking. Eluted proteins were
resolved by SDS–PAGE and stained with Coomassie G-250 to
verify protein purity, Rab8 and LRRK2 protein concentration
was calculated by densitometry, using a standard curve with
bovine serum albumin (BSA). Phosphorylation reactions were
performed in kinase buffer in presence of LRRK2 20 nM and
Rab8 300 nM (where indicated) and 1 mM ATP at 30◦C for
1 h in a final volume of 30 µl. Reactions were terminated
with 4× Laemmli buffer and by boiling at 95◦C for 10 min.
Samples were separated by SDS-PAGE or taking advantage of
PhosTag gel to discriminate phosphorylation status as previously
described (Civiero et al., 2017). Briefly, to perform PhosTag
analysis, samples were supplemented with 10 mMMnCl2 before
loading gels. Gels for Phos-tag Tris-glycine polyacrylamide gels
consisted of a stacking gel [4% (w/v) acrylamide, 125 mM
Tris/HCl, pH 6.8, 0.1% (w/v) SDS, 0.2% (v/v) TEMED and 0.08%
(w/v) APS] and a separating gel [7.5% (w/v) acrylamide, 375 mM
Tris/HCl, pH 8.8, 0.1% (w/v) SDS, 75 µM Phos-tag acrylamide,
150 µMMnCl2, 0.1% (v/v) TEMED and 0.05% (w/v) APS]. After
eletrophoretic separation, samples were transferred onto PVDF
membranes (Bio-Rad) using the Trans-Blot Turbo Transfer
System (Bio-Rad) in semi-dry conditions using Trans-Blot Turbo
Transfer Buffer (Bio-Rad) in 20% (v/v) ethanol at 25 V for
20 min. Membranes were blocked for 40 min in 5% (w/v)
skimmed milk in TBS-T buffer (20 mM Tris-HCl pH 7.4,
150 mMNaCl, 0.1% (v/v) Tween-20), followed by incubation for
1 h with an antibody against the LRRK2 autophosphorylation
sites Thr2483 (MJF-R8, Abcam, 1:2000) and Ser1292 (Abcam,
1:2000), total LRRK2 (MJFF2, Abcam 1:2000) and FLAG
epitope (Sigma, 1:1000). Membranes were washed four times
for 10 min with TBS-T buffer and incubated for 1 h at room
temperature with HorseRadish-Peroxidase (HRP)-conjugated
rabbit secondary antibodies (1:15,000) in 5% (w/v) skimmed
milk in TBS-T buffer. Membranes were washed in TBS-T buffer
followed by visualization using ECL Western Blotting Detection
Reagents (GE Healthcare). Densitometry analysis carried out
using ImageJ software was performed and data were expressed
as phospho/total LRRK2 protein levels.
Size Exclusion Chromatography
Lysates (0.5 ml) from WT and E193K fibroblasts were
separated on a Superose 6 10/300 column (Ge Healthcare,
Waukesha, WI, USA) pre-equilibrated with 20 mM Tris-HCl
pH 7.5, 150 mM NaCl and 0.06% (v/v) Triton X-100. The
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flow rate used was 0.5 ml/min. Fractions of 0.25 ml were
collected, and 1 µl spotted onto a nitrocellulose membrane
and analyzed by dot blot. The membrane was blocked with
10% milk in TBS plus 0.1% Tween-20 (TTBS) and incubated
with rabbit monoclonal anti-LRRK2 (MJFF2, Abcam, 1:2000)
and subsequently, HRP-conjugated rabbit secondary antibodies
(1:15,000) in TTBS with 10% milk. Immunoproteins were
visualized using ECL (GE, Healthcare, Waukesha, WI, USA).
Homology Modeling
Modeling templates were identified in the Protein Data Bank
(Berman et al., 2002) using the profile-profile alignment program
Phyre2 (Kelley et al., 2015). The initial homology model was
build based on the ARM domain structure of adenomatous
polyposis coli (APC) protein from human (PDB code: 3T7U).
The model structure was further refined using the YASARA
energy minimization server to increase the model accuracy
(Krieger et al., 2002). The quality of final structure model was
validated using PROCHECK (Laskowski et al., 1996). PyMOL1
was used for visualization of the final model.
Statistical Analysis
All data are expressed as the mean ± standard error of the mean
(SE). All data were logged into PRISM and were analyzed with an
unpaired Student’s T-test (two classes) or ANOVA followed by
Tuckey’s post hoc test (more than two classes). The indications of
the number of experiment (n) and the level of significance (p) are
indicated throughout the text.
RESULTS
Identification of LRRK2 E193K Variant
We performed exome sequencing in an Italian family with three
affected siblings (Figure 1A).
In the three brothers, symptoms were typical of idiopathic
PD with onset around 46–48 years in all cases (Figure 1B).
Progression was slow, and none developed cognitive decline. A
more detailed clinical description is reported in supplementary
material. Two of the three PD cases in the family (G-0502,
G-1350) are being followed at the Parkinson Center of
Milan. Analysis of the major PD genes did not reveal any
pathogenic mutation: Parkin, PINK1, DJ-1, SNCA, GBA,
LRRK2 (exon 31 and 41). These same two patients were
analyzed by whole-exome sequencing. One interesting novel
variant in the LRRK2 gene, c.577G>A, causing the missense
change p.E193K, was present, in the heterozygous state,
in all three affected siblings (Figure 1C). We tested this
variant in the other relatives: the same G>A transition was
present as well in two healthy relatives (G-1642 and G-1644)
suggesting incomplete penetrance as reported for the other
LRRK2 mutations identified so far (Goldwurm et al., 2011).
This variant is absent from public mutation databases (GnomAD
Browser) and ethnically matched controls (about 1800 Italian
exomes).
1http://www.pymol.org/
The E193K Variant Affects
LRRK2 Biochemical Features
In silico prediction suggests that the highly conserved
E193 residue is located within the armadillo repeats domain.
Structural modeling for the armadillo repeats indicates that
E193 residue is solvent-exposed (Figure 2A). Being LRRK2 a
kinase, we first investigated the potential impact of E193K
variant on LRRK2 catalytic properties. Autophosphorylation
is a recognized output of LRRK2 specific kinase activity
(Greggio et al., 2008; Sheng et al., 2012). Thus, we compared
the autophosphorylation activity of LRRK2 WT vs. E193K
variant. We immunoprecipitated FLAG-LRRK2 variants from
transfected HEK293 cells and performed in vitro radiometric
phosphorylation assays. LRRK2 WT and E193K variant
possess comparable autophosphorylation levels as judged
by total P33 incorporation (Figures 2B,C). We obtained
similar results investigating by western-blotting two specific
LRRK2 autophosphorylation sites, Ser1292 and Thr2483
(Sheng et al., 2012; Figures 2D–F). Rab8 is a well established
substrate of LRRK2 (Steger et al., 2016). Thus we evaluated
the efficiency of the phosphorylation of LRRK2 WT, E193K
and the artificial kinase-dead variant K1906M on Rab8 with
PhosTag gels coupled with immunoblot analysis. We found that
LRRK2 WT and E193K variant phosphorylates Rab8 protein in
a similar extent in vitro after 60 min incubation under kinase
assay conditions, as revealed by the retarded electrophoretic
mobility of phosphorylated Rab8 (Figures 2G,H). These data
suggest that E193K has no major impact on LRRK2 kinase
activity. Phosphorylation at Ser935 is altered in the presence
of multiple PD mutations (Nichols et al., 2010). Therefore,
we profiled LRRK2 phosphorylation at Ser935 in WT and
E193K primary fibroblasts. Western-blotting analysis showed
that while LRRK2 total levels do not differ substantially
between the two lines, phospho-Ser935 level is impaired
in fibroblast carrying the E193K variant (Figures 3A–C).
We obtained a similar result by western-blotting analysis
of LRRK2 Ser935 phosphorylation in N2A cells upon
over-expression of LRRK2 variants (Supplementary Figures
S1A,B). Phosphoresidues at Ser910/935 stabilize LRRK2 binding
to 14-3-3s chaperons (Dzamko et al., 2010). Given the impact of
E193K substitution on Ser935 phosphorylation, we investigated
the effect of E193K on LRRK2 binding to 14-3-3ε. To this aim,
we expressed myc-tagged LRRK2 WT or E193K variant together
with FLAG-14-3-3ε in N2A cells (Gloeckner et al., 2007).
After solubilization, we immobilized 14-3-3ε on anti-FLAG
beads, and we studied the amount of bound LRRK2 variant
by western-blotting. Noteworthy, E193K demonstrated a
significantly reduced affinity for 14-3-3ε compared to WT
LRRK2 (Figures 3D,E). 14-3-3 binding to phosphorylated
Ser935 influences LRRK2 sub-cellular distribution (Nichols
et al., 2010). Thus, we studied the cellular localization of RFP
LRRK2 WT and E193K variant upon over-expression in N2A
cells. We noticed that while LRRK2 WT was diffuse within
the cytosol, E193K variant appeared in perinuclear clusters
(Figure 3F). The armadillo repeats domain allows interaction
with other proteins: E193K variant may, therefore, affect
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FIGURE 1 | Simplified pedigree of the analyzed family. (A) Symbols with black upper corner indicate individuals affected by Parkinson’s disease (PD). Age of onset of
PD (years) is reported; in the patients’ relatives, age at last examination or age at death is reported. The result of leucine-rich repeat kinase 2 (LRRK2) genetic
screening for the mutation was either wild type (WT) or heterozygous carrier (E193K). Gender of healthy siblings has been masked to protect the anonymity of the
families. (B) The table summarizes clinical data of the three E193K carriers. (C) Sequencing of PCR product from exon 6 of WT and mutant alleles. The upper
chromatogram of the portion of the sequencing gel shows the wild allele and the lower the heterozygous mutant allele.
LRRK2 homo and hetero interaction. To test this hypothesis,
we analyzed LRRK2 E193K elution profile by means of size
exclusion chromatography (SEC) experiments in samples
prepared from primary fibroblasts derived from an E193K
carrier or healthy subjects (Figure 4A). Interestingly, the
elution profile of LRRK2 E193K substantially differs from
the one of WT LRRK2, with the appearance of a robust
peak in the low-molecular weight fractions (fraction 14,
Figure 4B). To complement this evidence, we performed a
filter retardation assay to detect the presence of high molecular
weight (HMW) protein complexes including LRRK2. By
western-blotting, we detected a substantial reduction of HMW
LRRK2-positive complex in specimen prepared from E193K
fibroblasts (Figures 4C,D). Altogether these data suggest
that the E193K substitution impacts LRRK2 supra-molecular
organization.
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FIGURE 2 | E193K variant does not affect LRRK2 kinase activity. (A) Ribbon diagram showing a structural homology model (based on the ARM domain of
adenomatous polyposis coli (APC) protein from human, PDB: 3T7U) for the LRRK2 N-terminal region (residues 7-322). N-terminus (N) and C-terminus (C) of the
structural model as well as the position of E193 (stick model) are indicated. (B) In vitro radioactive kinase assays of 3x-Flag LRRK2 WT and E193K purified from HEK
cells. Five nanomolar of purified Flag-LRRK2 WT or E193K from HEK293T cells were subjected to in vitro radiometric kinase assays and the radioactivity
incorporated was quantified by PhosphoImager. Upper panel represents autophosphorylation and lower panel western blotting with anti-flag antibodies to quantify
total loading. (C) Quantification of moles of 33P incorporated by LRRK2. Graphs report mean ± standard error (SE), n = 4. (D) In vitro kinase assays as in (A). Five
nanomolar of purified Flag-LRRK2 WT or E193K from HEK293T cells were also subjected to in vitro non-radioactive kinase assays. Autosphosphorylation levels were
measured by western blotting with anti-Ser1292 and anti-Thr2483 antibodies (upper panels). Lower panel represents total protein loading, probed with anti-flag
antibodies. (E) Quantification of phosphorylation at Thr2483 and (F) Ser1292, expressed as optical density and normalized vs. total LRRK2 protein amount. Graphs
report mean ± SE, n = 4. (G) Purified Flag-LRRK2 WT, E193K or K1906M protein were incubated with Flag-Rab8 (1:15 molar ratio) in the presence or absence of
1 mM ATP and subjected to PhosTag assay to analyze phosphorylation stoichiometry and SDS-PAGE to verify total protein amount. Anti-Flag antibody was used to
reveal LRRK2 and Rab8. (H) Quantification of Rab8 phosphorylation, expressed as optical density and normalized vs. total Rab8 (phosphorylated +
unphosphorylated band). Data are presented as mean ± SE (n = 3); ∗∗ p < 0.01 vs. -ATP, same LRRK2 variant.
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FIGURE 3 | E193K variant affects LRRK2 phosphorylation at Ser935. (A) Protein lysate prepared from primary fibroblast obtained from healthy individuals or E193K
carrier was analyzed by western-blotting to appreciate total LRRK2 level and phosphorylation at Ser-935. (B,C) The graphs report LRRK2 total level, expressed as
optical density and normalized vs. β-tubulin amount (B) and P-Ser935 level, expressed as optical density and normalized vs. total LRRK2 amount (C). Data are
shown as mean ± SE, n = 8; ∗∗∗p < 0.001 vs. WT. (D) N2a cells expressing FLAG-14-3-3ε together with myc-LRRK2 WT or myc-LRRK2 E193K variant were
solubilized and processed for FLAG immunopurification. We evaluated the extent of LRRK2 binding to 14-3-3ε by measuring the amount of myc LRRK2
co-precipitating with FLAG 14-3-3ε (E) The graph reports the amount of myc-LRRK2 variant recovered in FLAG immunoprecipitates. Data were normalized to the
amount of 14-3-3ε immunoprecipitated and expressed as mean ± SE, n = 4; ∗∗p < 0.01versus WT. (F) N2a cells expressing GFP together with RFP-LRRK2 WT or
RFP-LRRK2 E193K variant were processed for imaging purposes. Scale bar = 10 µm.
E193K Variant Affects Mitochondrial
Response to MPP+
One of the most recognized pathological events in PD is
mitochondrial dysfunction, and LRRK2 has been proposed to
be associated with mitochondrial biology (Biskup et al., 2006;
Verma et al., 2017). LRRK2 influences mitochondrial dynamics
(Wang et al., 2012) and response to toxins (Saha et al., 2009).
Therefore, we analyzed the impact of the LRRK2 E193K variant
on cell viability upon exposure to the mitochondrial toxin
MPP+. To this aim, we treated primary fibroblasts obtained
from healthy individuals, E193K and G2019S carriers with
increasing concentrations of MPP+ and we evaluated cell
Frontiers in Molecular Neuroscience | www.frontiersin.org 8 February 2018 | Volume 11 | Article 64
Perez Carrion et al. E193K Influences LRRK2-DRP1 Complex
FIGURE 4 | E193K variant affects LRRK2 supra-molecular organization. (A) Protein lysate prepared from primary fibroblast obtained from healthy individuals or
E193K carrier was separated by size exclusion chromatography (SEC). LRRK2 elution profile was revealed by dot-blot using anti-LRRK2 antibody. Theoretical
molecular weight are: V0 at fraction 8.5, 669 kDa at fraction 12, 449 kDa at fraction 13. (B) The graph reports the intensity of each dot (fraction) normalized by the
integrated intensities. Data are shown as mean ± SE, n = 4; ∗p < 0.05 vs. WT. Column void volume is 7.5 ml. (C) Primary fibroblasts obtained from healthy
individuals or an E193K carrier were assayed by filter retardation assay to isolate high molecular weight (HMW) form of LRRK2 on acetate cellulose membrane and
total LRRK2 on nitrocellulose membrane. (D) The graph reports LRRK2 HMW amount expressed as fold over total LRRK2. Data are shown as mean ± SE, n = 8;
∗∗p < 0.01 vs. WT.
viability by MTT assays (Figure 5A). The treatment with
3 mM MPP+ triggered cell death in all cell lines despite
the different genotype. Noteworthy, we noticed that 1 mM
MPP+ did not result in overt toxicity in WT fibroblasts but
resulted noxious for E193K and, as expected, for G2019S cells
(Yakhine-Diop et al., 2014). MPP+ accumulates in mitochondria
(Ramsay and Singer, 1986), and high concentrations of MPP+
partially inhibit mitochondrial complex I activity (Nicklas et al.,
1985). Therefore, we examined the mitochondrial respiration
in primary fibroblasts using a high-resolution respirometer
(Figure 5B and Supplementary Figure S1F). Fibroblasts from
healthy subjects, E193K or G2019S carriers showed an almost
similar respiratory activity under basal conditions. Upon 1 mM
MPP+ treatment, we measured a robust drop of routine
respiration in all lines. We noticed subtle differences among
the different genotypes while analyzing complex I and II
and maximal respiration activity. In particular, E193K and
G2019S lines were more sensitive to MPP+ in terms of
complex I and II and maximal respiratory capability. Aberrant
functioning of the mitochondrial respiratory chain can induce
the production of noxious ROS. Therefore, we measured ROS
production in basal conditions and upon 1 mM MPP+ insult.
To this aim, we incubated primary fibroblasts with MitoSOX
Red, a fluorogenic dye selective for mitochondrial superoxide
(Figure 5C). Interestingly, while 1 mM MPP+ treatment
did not result in an overt increase of ROS production in
control or G2019S fibroblasts, it almost doubled ROS level in
E193K cells (Figure 5D). MPP+ affects mitochondrial structural
organization (Zhu et al., 2007). For the reliable preservation
of the dynamically changing mitochondrial ultrastructure, we
chose rapid cryo-fixation through use of high-pressure freezing,
instead of conventional chemical fixation. In WT and G2019S
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FIGURE 5 | E193K mitochondria are more sensitive to MPP+. (A) Primary fibroblasts obtained from healthy individuals, E193K or G2019S carriers were treated with
1 or 3 mM MPP+ for 24 h and cell vitality was measured by the means of MTT assays. The graph reports relative viability. Data are shown as mean ± SE, n = 6;
∗∗∗p < 0.001 vs. control conditions, same genotype, #p < 0.05 vs. WT, same treatment. (B) Oxygen consumption assessed by high resolution respirometry of
primary fibroblasts after 24 h treatment with 1 mM MPP+. The graph reports routine activity (routine respiration), complex I and complex II—dependent activity (upon
treatment with malate, glutamate and succinate) and maximal activity (maximal uncoupled respiration after FCCP injection). Data show means ± SE, n = 4; ∗,
∗∗p < 0.05, 0.01 vs. control conditions, same genotype. (C) Primary fibroblasts obtained from healthy individuals, G2019S or E193K carriers were treated with 1 mM
MPP+ for 24 h and then incubated with Mitosox to measure the reactive oxygen species (ROS) production. Scale bar = 25 µM. (D) The graph reports the intensity of
the Mitosox signal, expressed as integrated density. Data are expressed as mean ± SE, n = 4 (20 cells/experiment); #p < 0.05 vs. control condition, same genotype.
∗, ∗∗p < 0.05, 0.01 vs. WT, same treatment.
fibroblasts, MPP+ induced dramatic alterations in mitochondrial
morphology. Mitochondria appeared locally highly dilated,
consistently showing disorganized cristae. Furthermore, the
mitochondrial shape had changed from branched tubules (as
observed in untreated samples) to spherical and rod-shaped
fragments. In untreated E193K fibroblasts, size and shape of
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mitochondria were almost normal. However, upon MPP+ insult,
mitochondria in E193K fibroblasts appeared as segmented,
highly anastomosing networks with partially disorganized cristae
(Figure 6 and Supplementary Figure S2), indicating impaired
fission. Altogether, these data suggest that the E193K variant
influences functional and structural mitochondrial response to
toxins.
E193K Variant Alters LRRK2 Affinity for
DRP1
Mitochondria react to toxic insult by activating a cycle of
fusion-fission events (Wang et al., 2011). Among the panel
of proteins regulating mitochondrial fission, DRP1 plays a
major role (Chang and Blackstone, 2010). DRP1 has been
suggested as a LRRK2 interactor (Wang et al., 2012). First, we
confirmed LRRK2-DRP1 interaction by immunoprecipitation
of endogenous LRRK2 from mouse brain lysate (Figure 7A).
LRRK2 harbors at least two major sites for protein interaction
featured by its N- and C-terminus (Carrion et al., 2017). Thus, we
mapped the LRRK2 domain hosting the interaction with DRP1.
To this aim, we expressed Strep-FLAG LRRK2 full-length (full
length), Strep-FLAG LRRK2 missing the N-terminal fragment
(∆N-terminal) and Strep-FLAG LRRK2 missing the C-terminal
WD40 domain (∆WD40) in HEK293 cells. Upon streptavidin-
pull-down, we studied interacting proteins by western-blotting.
Interestingly, we noticed that the interaction with DRP1 was
severely reduced in the LRRK2∆N-terminal variant (Figure 7B).
Next, we investigated whether the E193K variant might affect
FIGURE 6 | Mitochondrial morphology is impaired in E193K fibroblasts. Transmission electron microscopy from cryo-fixed, freeze-substituted fibroblast cultures.
Untreated WT, G2019S or E193K fibroblasts showed elongated, partly branched mitochondria with correctly arranged cristae. Upon treatment with MPP+, WT and
G2019S fibroblasts appeared consistently fragmented (and locally highly swollen), showing reduced and disorganized cristae. By contrast, E193K fibroblasts were
regularly characterized by conspicuously segmented, highly anastomosing mitochondrial networks and altered cristae morphology. Representative images are
shown from three independent cell culture experiments (20 cells genotype/treatment/experiment). Scale bar = 500 nm.
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FIGURE 7 | E193K variant affects LRRK2-DRP1 complex. (A) Extracts of mouse adult forebrain were incubated with anti-LRRK2 antibodies or rat IgG. The
immunocomplexes were isolated with protein G-Sepharose and the samples were resolved by SDS-PAGE and analyzed by immunoblotting with anti DRP1 and anti
LRRK2 antibodies. Arrowhead indicates unspecific band recognized by anti-rabbit secondary antibody. (B) We isolated on streptavidin resin strep-FLAG-LRRK2
full-length (full-length), strep-FLAG-LRRK2∆WD40 (∆WD40) and strep-FLAG-LRRK2∆N–terminal (∆N–terminal) protein from HEK293 over-expressing cells.
Interacting proteins were resolved by western-blotting. (C) We performed a GST-pull down approach to explore the interactome associated to LRRK2 N-terminal
Armadillo domain. GST-fusion proteins corresponding to Armadillo domain of LRRK2 WT and LRRK2 E193K (E193K) were used to retain interactors from adult
forebrain lysate. The complexes were isolated with GSH-Sepharose beads, the samples were resolved by SDS-PAGE and analyzed by immunoblotting with anti
DRP1 and anti P-Ser616 DRP1 antibodies. (D) We evaluated the extent of DRP1 and P-Ser616 DRP1 bound to WT and E193K Armadillo domain expressed as ratio
over WT domain. Graph reports mean ± SE; n = 4; ∗∗p < 0.01 vs. WT. (E) N2A cells expressing Strep-FLAG-LRRK2 WT or Strep-FLAG-LRRK2 E193K variant were
treated or not with MPP+ (1 mM, 24 h) solubilized and processed for streptavidin immunopurification. We evaluated the extent of DRP1 binding to LRRK2 by
measuring the amount of DRP1 protein co-precipitating with Strep-FLAG LRRK2 variant. (F) The graph reports the amount of DRP1 recovered in FLAG
immunoprecipitates. Data were normalized to the amount of LRRK2 variant immunoprecipitated and expressed as mean ± SE, n = 7; ∗p < 0.05 vs. WT,
##p < 0.01 vs. E193K not treated.
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LRRK2-DRP1 interaction taking advantage of a domain-wise
pull-down approach. To this aim, we expressed LRRK2 Arm
WT and E193K domain as GST fusion proteins (from now
on termed as Arm wt and Arm E193K). GST-only served as
control, to detect false positives caused by unspecific binding
to the affinity tag or matrix. By western-blotting, we noticed
that Arm E193K variant binds total DRP1 as well as the active
form, phospho-616 DRP1 (Taguchi et al., 2007) with increased
efficiency (Figures 7C,D). To further test the impact of E193K
variant on the LRRK2 binding feature, we isolated full-length
FLAG-LRRK2 WT and E193K protein from transfected N2A
cells and studied LRRK2 binding to DRP1 and mitofusin-2,
a protein involved in mitochondrial fission (Ishihara et al.,
2004) previously proposed as LRRK2 interactor (Stafa et al.,
2014). Again, E193K variant demonstrated a robustly increased
affinity for DRP1 while the binding with mitofusin-2 was not
affected (Figures 7E,F and Supplementary Figures S1C–E).
Next, we studied the LRRK2-DRP1 complex in the presence
of MPP+ (1 mM). Interestingly, we found that upon MPP+
the binding between LRRK2 E193K and DRP1 was significantly
impaired while the LRRK2 WT/DRP1 complex remained
stable (Figures 7E,F). Given the key role played by DRP1 in
mitochondrial fission and the impact of E193K variant on
LRRK2-DRP1 complex, we investigated the mitochondrial
response to MPP+ in healthy and E193K fibroblasts upon
over-expression of GFP or GFP-DRP1. Living fibroblasts were
treated with MPP+ (1 mM, 24 h) or vehicle and then
incubated with MitotrackerRed (Figure 8A and Supplementary
Figure S3). MPP+ insult caused mitochondria fragmentation
in GFP or GFP-DRP1 expressing WT fibroblasts, as reflected
by reduced interconnectivity and length of mitochondria. By
contrast, in GFP-expressing E193K cells MPP+ did not induce
overt mitochondrial fission. We observed a similar outcome
in HeLa cells upon over-expression of LRRK2 variants and
MPP+ treatment (Supplementary Figure S4). Interestingly,
we noticed that GFP-DRP1 over-expression correlated with
mitochondrial fission upon MPP+ insult in E193K fibroblasts
(Figures 8B,C and Supplementary Figure S3). Altogether, these
data suggest that the E193K variant affects mitochondrial
fission upon MPP+ exposure by influencing LRRK2-DRP1
complex.
DISCUSSION
We described here the functional impact of the E193K
substitution on LRRK2 identified in one Italian family with
three PD-affected siblings. Despite the fact that the mutation
is very rare and likely a private mutation, we believe that an
extensive functional characterization of this variant could help
in elucidating LRRK2 tasks. This protein has a key role in
PD pathogenesis, influences autophagy and mitochondrial
function and may be an important therapeutical target for
idiopathic PD (Wang B. et al., 2016). In particular, our
data bring further support to the hypothesis that LRRK2 is
implicated in mitochondrial homeostasis. Accumulating
literature has demonstrated the link among mitochondrial
dysfunction, oxidative stress and the pathogenesis of multiple
neurodegenerative disorders including PD (Bose and Beal,
2016). This does not come unexpectedly: mitochondrial function
is essential to cellular processes such as energy production
and ions regulation. Furthermore, neurons do have special
energetic needs to fuel axonal and dendritic transport, the release
and re-uptake of neurotransmitters and vesicle trafficking
at synapses. Mitochondria go through continuous cycles of
fusion and fission. Various PD-associated proteins are involved
in the regulation of mitochondrial dynamics. PINK1/Parkin
regulates the ubiquitination and degradation of mitofusin 2 and
DRP1while LRRK2 increases DRP1 recruitment tomitochondria
(Luo et al., 2015). LRRK2 PD mutations increase vulnerability
to mitochondrial stress (Saha et al., 2009; Wang et al., 2012) but
the precise mechanism underlined has not been fully understood
yet. We describe here that the E193K variant has no major
impact on mitochondrial basal activity but instead increases
susceptibility to MPP+. This comes in good agreement with
the GxE theory underlying PD. The exposure to stressors and
genetic factor(s) together can trigger the degenerative cascade
(Bose and Beal, 2016). The E193K substitution falls within the
armadillo repeats domain. Armadillo repeats fold together into
a superhelix, which constitutes a versatile platform for multiple
protein interactions (Tewari et al., 2010). The substitution of
a negatively charged residue, E, with a positively charged one,
K, is strongly predicted to influence the biochemical properties
of the N-terminal Armadillo domain of LRRK2. We found that
the E193K substitution alters the binding between LRRK2 and
DRP1 (Wang et al., 2012). Among its several functions, it
is well established that DRP1 executes mitochondrial fission
(Chang and Blackstone, 2010). In particular, it is a crucial
mediator of mitochondrial fission upon MPP+ treatment (Wang
et al., 2011). It has been suggested that upon initial fission,
DRP1 complex must be removed from the mitochondrial outer-
membrane to allow the full separation of the formed segment,
i.e., fragmentation. Otherwise, DRP1 exerts an inhibitory action
due to the occupancy of fission sites, sequestration of other
effectors or steric hindrance (Zhao et al., 2011; Wang W. et al.,
2016). Accumulating evidence suggests that mitochondrial
fragmentation precedes mitophagy. In particular, the activity of
DRP1 correlates well with mitochondrial fission and autophagy:
increased DRP1 activity facilitates mitochondrial elimination
under noxious stimuli and the expression of a DRP1 dominant
negative isoform impaired mitophagy (Arnoult et al., 2005).
These observations suggest that fission is instrumental for
mitochondrial fragmentation, which might be seen as a rescue
mechanism that permits the segregation and elimination of
dysfunctional mitochondria. LRRK2 directly interacts with
DRP1 and increases DRP1 recruitment to mitochondria (Wang
et al., 2012). Given the reduced affinity for DRP1 demonstrated
by E193K LRRK2 upon MPP+ treatment, it can be argued that
E193K substitution may partially destabilize the DRP1 complex
at mitochondria in the presence of a toxic insult. This may lead
to incomplete fragmentation of mitochondria that prevents
the autophagic clearance of damaged organelles (Gomes et al.,
2011). Accordingly, while in control fibroblasts mitochondria
underwent evident fragmentation, we consistently observed
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FIGURE 8 | Mitochondrial fission upon MPP+ is impaired in E193K fibroblasts. (A) Primary fibroblasts obtained from healthy individuals and an E193K carrier were
transfected with GFP or GFP-DRP1, treated with 1 mM MPP+ for 24 h and then incubated with MitotrackerRed to investigate mitochondrial morphology. Scale
bars = 10 µm. (B,C) The graphs report mitochondrial interconnectivity (B) and content (C). Data are expressed as mean ± SE (n = 4, 5–6 cells/experiment);
◦◦p < 0.01 vs. control treatment, same transfection, ∗∗∗,◦◦◦p < 0.001 vs. control treatment, same transfection, #p < 0.05 vs. GFP MPP+.
the appearance of segmented, highly branched mitochondria
in E193K cells upon MPP+. Damaged mitochondria are a
source of oxidative stress (Twig et al., 2008): not surprisingly
we noticed increased ROS production and cellular toxicity in
E193K cells upon MPP+. Interestingly, G2019S fibroblasts were
characterized by increased susceptibility to MPP+ as compared
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FIGURE 9 | The E193K variant prevents mitochondrial fission upon MPP+ treatment. (A) Under basal conditions mitochondria undergo continuous cycles of fusion
and fission. Fission requires the activity of DRP1. LRRK2 binds to DRP1 and increases DRP1 recruitment to mitochondria. (B) Under noxious stimuli, WT cells react
via the LRRK2-DRP1 complex that allows mitochondrial fission (1). Eventually, damaged mitochondria are eliminated via autophagy (2) limiting the production of
ROS. (C) In the presence of a toxic insult the LRRK2 E193K-DRP1 complex is partially destabilized. This leads to an incomplete fragmentation of mitochondria that
prevents the clearance of damaged organelles and increases the production of ROS.
to E193K line in terms of viability and mitochondrial respiration
but demonstrated mitochondrial fragmentation as WT lines did.
Thus, G2019S and E193K might affect mitochondrial response
to toxins acting on different pathways. Recently, it has been
reported G2019S mutation may alter mitochondrial calcium
currents (Verma et al., 2017). Our data indicate that E193K
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variant alters the dynamics of LRRK2-DRP1 complex upon
MPP+ exposure. Thus we hypothesize that the E193K variant
interferes with the stress-induced turnover of the LRRK2-DRP1
complex thus impairing autophagic removal of damaged
mitochondria and eventually increasing cellular sensitivity to
noxious stimuli (Figure 9). We have previously demonstrated
that LRRK2 acts as a scaffold at the presynaptic site where it
influences vesicle recycling via protein-protein interactions
(Piccoli et al., 2011, 2014; Bedford et al., 2016; Carrion et al.,
2017). Furthermore, LRRK2 binds and phosphorylates Rab
proteins, the master regulators of membrane fusion (Steger
et al., 2016). Thus, one intriguing hypothesis is that LRRK2 acts
as a molecular hub that organizes structural and regulatory
elements to control proper trafficking of different membranous
structures, from synaptic vesicles to mitochondria. We are
well aware of the potential bias due to the intrinsic features
of a given primary fibroblast line. However, we succeeded in
recapitulating our key findings obtained in primary fibroblasts
in heterologous lines upon over-expression of the LRRK2 E193K
variant. Thus, we are confident that our study addressed
specifically the biological effect of the E193K substitution. The
E193K variant might affect LRRK2 function via perturbation
of its physiological network of interactors. It has been shown
that several LRRK2 variants as A1442P, R1441C and the
G2385R affect LRRK2 steady-state levels (Greene et al., 2014;
Rudenko et al., 2017): thus it deserves further investigation the
possibility that E193K variant might impact LRRK2 protein
turn-over. Intriguingly, at the other side of the protein, the
G2385R point mutation within the WD40 domain perturbs
LRRK2 biochemical features and influences LRRK2 functions
(Jorgensen et al., 2009; Rudenko et al., 2012; Piccoli et al., 2014;
Carrion et al., 2017). Thus, the regulation of the LRRK2 protein
complex is emerging not only as a key factor in its physiological
and pathological function but could arise as a target for
future therapeutic approaches besides the LRRK2 kinase
activity.
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